Burning Rock and CStone Pharmaceuticals reached a strategic collaboration on the co-development of companion diagnostics for pralsetinib in China

    NEXT STORY
    Press release Oncology Venture signs agreement to out-license two pipeline assets as part of prioritized portfolio strategy
    PREV STORY
    Cell Publication Elucidates How SARS-CoV-2 Dramatically Rewires Important Cell Programming; Identifies Existing Therapeutics That May Fight COVID-19
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron’s PD-1 Inhibitor

    Phase 1/2 clinical trial combines Regeneron’s PD-1 inhibitor cemiplimab and Inovio’s immunotherapy INO-5401 in ...

    author_avatar
    NASDAQ Market News

    Sonoma Pharmaceuticals Announces Substantial Cost-Cutting Measures

    author_avatar
    NASDAQ Market News

    Dermavant Enters into Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan

    author_avatar
    NASDAQ Market News